ON THE PATH
TOWARD THE POSSIBLE

At Flare Therapeutics, we have built a novel pipeline of programs from select transcription factors with robust genetic and biologic validation, initially focused on precision oncology with lead programs in advanced urothelial cancer and prostate cancer. With our ability to integrate TF structure and genetics alongside our proprietary, context-dependent electrophilic libraries, we have discovered and developed the first clinical-stage small molecule inhibitor of PPARG, a master regulator of the luminal lineage, and a powerful degrader of the androgen receptor (AR) that leverages a novel pocket that uniquely targets the hormone-bound, active form. This approach is differentiated from all other approaches that target AR in the hormone unbound state, leaving these approaches susceptible to AR-driven mutations and other genetic alterations such as gene amplification.

Further, we are applying our discovery engine to early discovery programs in metabolic, neurology, immunology/inflammation and rare genetic disorders driven by transcriptional dysregulation.